ADC Therapeutics' Q2 2026 print landed on August 13 with two material developments sitting on top of each other: $18.6 million of ZYNLONTA net product revenue, up just 3.0% year-over-year and roughly flat sequentially, and a Food and Drug Administration pre-supplemental Biologics License Application meeting response that is materially more cautious than the LOTIS-5 topline suggested. The Phase 3 LOTIS-5 trial of ZYNLONTA plus rituximab in second-line-plus diffuse large B-cell lymphoma met its progression-free survival primary endpoint with statistical significance (hazard ratio 0.73, p=0.0084), but the agency raised "substantial concerns" about the imbalance in Grade 5 treatment-emergent adverse events (13.2% on the ZYNLONTA arm versus 4.6% on rituximab-gemcitabine-oxaliplatin) when weighed against what the agency characterized as a marginal treatment benefit. Management is now assessing the regulatory path rather than preparing a near-term filing, and the company is exploring whether the LOTIS-7 bispecific combination - a 90% overall response rate, 78% complete response rate data set in a much smaller Phase 1b - can anchor a Phase 3 program in the same second-line-plus setting.
The equity case for ADC Therapeutics, which is a clinical-stage-biotech-style trade on optionality layered on top of a single commercial product, has been repriced hard. The shares closed at $1.01 on August 14, 2026, down roughly 70% from the $3.40 level on June 1, 2026 immediately before the LOTIS-5 topline release, and the all-time pattern is now one of a small-cap oncology name with $219.1 million of cash and a single approved product, where the entire investment case has migrated from "LOTIS-5 converts accelerated approval to full approval and unlocks earlier lines" to "LOTIS-7 is the real prize and the commercial asset is a cash-flow anchor that funds the optionality." The risk to that trade is that the Grade 5 imbalance in LOTIS-5 reads through to LOTIS-7, which is a different combination but the same payload chemistry. The next data point is the full LOTIS-7 presentation at the American Society of Hematology meeting in December 2026, and the next regulatory data point is the company's own update on the LOTIS-5 path, which management committed to in the "near future."